A world leader in innovative therapies, Novartis has developed treatments that extend and improve the lives of cancer patients.
In Brazil for 90 years, Novartis (whose operations cover 150 countries) reinvents medicine to provide innovations and high-tech medicines that offer treatment possibilities that change the course of diseases, improving and prolonging the quality of life of each patient. To this end, the company favors investments in partnership projects with public and private health ecosystems, facilitating access to new therapeutic technologies for various diseases, including cancer.
CAR-T cell therapy
In 2022, Novartis made the first CAR-T cell therapy available in Brazil. Gained regulatory approval for Brazil’s first cell therapy (CAR-T). “The therapy consists of extracting T lymphocytes, which are the body’s defense cells, from the patient’s body and modifying them in the laboratory so that, once returned to the body, the patient’s body and immune system can fight cancer,” says Cynthia Diaferia, director of Oncology at Novartis do Brasil.
Novartis also recently received approval from Anvisa for an innovative drug for a type of leukaemia. “It works differently than all other therapies available so far, with a mechanism that may represent a new option for patients resistant or intolerant to previous therapies,” says Cynthia.
Longer survival and therapeutic access
Currently, Novartis offers 25 oncology drugs in the country targeting diseases such as: breast cancer, multiple myeloma and bone metastases, among many others.
With the philosophy of being part of the global healthcare solution, the company also invests in partnerships with public healthcare systems. They, by the way, are changing the way most modern drugs are incorporated. “We aim to make a difference for millions of people by addressing the biggest challenge the healthcare ecosystem faces on a daily basis: sustainability, with our commitment to accelerate the patient journey from early diagnosis to access to the most innovative treatments,” reveals Cynthia.
Investing in the quality of life of patients
Novartis is one of the largest R&D investors in the world, investing approximately $9.1 billion in more than 200 projects. In Brazil alone, in the last four years, 1 billion dollars has been invested in studies and research, bringing more than 80 clinical trials to the country and training 20,000 health professionals.
These investments reflect the company’s progress in the development of innovative therapies in various therapeutic areas, as well as the construction of new technology platforms, such as cell, gene and radioligand therapies. “Radioligand therapies hold the promise of increasing survival and quality of life by delivering precision radiation to target cells anywhere in the body while helping to limit damage to surrounding healthy cells,” adds Cynthia.
Commitment to the entire healthcare ecosystem
Novartis understands that innovations in gene, cell, and radioligand therapies address important unmet needs in the treatment of disease. But it also understands that they bring new complexities – of development, provision, availability, access and other areas of the healthcare ecosystem. “Our commitment is to collaborate with the public and private system, hospitals, doctors, healthcare operators and payers for a rapid and adequate diagnosis, as well as for effective access to the best treatments, so that innovation arrives, in a timely manner, for the patients who need it”, completes Cinzia.
INNOVATION IN NUMBERS
In the past five years alone, Novartis has brought 18 innovative products to the country, including:
synthetics
biological
cell and gene therapies
Over the next five years, the company will offer more than 16 drugs in development.
Brazil is among the top 10 priority markets in the world for the company.
9 million patients treated with Novartis drugs 2,200 employees distributed in the factories, laboratory, administrative headquarters and field in various cities of the country.
Material intended for the lay public. BR-22274. Jul/23
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
